Acquiring Company
SenzaGen AB
Acquired Company
Alcyomics Ltd
Lund
Newcastle Upon TyneBiotechnologyBiotechnologyDescription
SenzaGen AB has completed the acquisition of Alcyomics Ltd. This acquisition strengthens SenzaGen's position in the non-animal testing segment of drug development. The total initial purchase price is approximately GBP 2.12 million, with potential earn-out payments. Alcyomics is now fully integrated into SenzaGen.
Who to call at SenzaGen AB, and when
When SenzaGen AB changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day SenzaGen AB raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SenzaGen AB, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SenzaGen AB. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SenzaGen AB makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Alcyomics Ltd?
Alcyomics Ltd was acquired by SenzaGen AB, based in Lund. The deal was reported on November 5, 2026. SenzaGen AB is a biotechnology company specializing in non-animal safety testing to support drug development. The company aims to enhance biomedical research through innovative solutions in immunotoxicology testing. SenzaGen AB is privately held and operates in Biotechnology.
When did SenzaGen AB acquire Alcyomics Ltd?
SenzaGen AB's acquisition of Alcyomics Ltd was reported on November 5, 2026. SenzaGen AB has completed the acquisition of Alcyomics Ltd. This acquisition strengthens SenzaGen's position in the non-animal testing segment of drug development. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Alcyomics Ltd do?
Alcyomics Ltd is a leading provider of non-animal immunotoxicology solutions for pharmaceuticals in the preclinical phase. The company focuses on biological anti-cancer drugs and utilizes human-based test platforms for safety testing. It is privately held, operating in Biotechnology, and is based in Newcastle Upon Tyne.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.